Heterozygous individuals with mild phenotype in late-onset glycogen storage disease type 2: a new cohort of patients? by L Vercelli et al.
POSTER PRESENTATION Open Access
Heterozygous individuals with mild phenotype in
late-onset glycogen storage disease type 2:
a new cohort of patients?
L Vercelli*, E Vittonatto, S Grifoni, L Chiadò-Piat, E Rolle, M Spada, C Danesino, G Comi, T Mongini
From Proceedings of the 6th European Symposium: Steps Forward in Pompe Disease
Berlin, Germany. 23-24 November 2012
Introduction
Late-onset glycogen storage disease type 2 (GSD2) is a
genetic but heterogeneous disorder, which may present
anywhere along a continuum of severity from an iso-
lated hyperCKemia to a profound, generalized muscle
weakness with pulmonary involvement. The gold stan-
dard for diagnosis is confirmation of low or absent
levels of acid alpha-glucosidase (GAA) enzyme activity
(usually in the range of 1-40% of normal levels), which
is confirmed only in some cases by molecular analysis of
the GAA gene. In the literature, heterozygous individuals
are usually considered to be asymptomatic, although
they can have reduced enzymatic activity. Since enzyme
replacement therapy (ERT) became available in 2006, it
has improved the prognosis for severe infantile-onset
Pompe disease, as well as for late-onset forms by
improving muscle/respiratory function and/or stabilizing
clinical progression. Because the disease is now treata-
ble, it is essential to understand which patients may
benefit from ERT.
Results
In the database of the Centre for Neuromuscular Dis-
eases, we found 7 patients with only one mutated GAA
allele: 2 female patients showed proximal weakness,
pathologic muscular biopsy and reduced GAA enzyme
activity in muscle tissue. These patients started ERT
four years ago, and now there is no evidence of disease
progression. The other 5 subjects (two are familiar
cases, one father and his son) have mild signs of myopa-
thy (i.e., slight scoliosis, proximal weakness, hyperlordo-
sis, fatigability, recurrent episodes of respiratory deficit)
or isolated hyperCKemia. Muscle biopsies showed non-
specific signs, and reduced enzymatic activity (below
40%) was confirmed in all patients using at least two
methods (dried blood spot and/or leukocytes and/or
muscle homogenate).
Conclusion
Heterozygotes with one GAA gene mutation are not
always asymptomatic individuals; in our experience, they
can develop a mild myopathy, have non-specific muscle
biopsy results, and reduced GAA enzyme activity. We
followed and monitored this cohort of patients (not
receiving ERT) and found that they did develop clinical
evidence of disease. In conclusion, mild symptomatic
subjects and heterozygotes are an emerging group of
patients. Further molecular investigations and follow-up
are required to identify patients in this cohort that may
benefit from ERT.
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